Patents by Inventor Ruey-Bing Yang
Ruey-Bing Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11866489Abstract: An isolated anti-SCUBE2 antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically binds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting VEGF-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or for use in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.Type: GrantFiled: June 8, 2021Date of Patent: January 9, 2024Assignee: ACADEMIA SINICAInventors: Ruey-Bing Yang, Yuh-Charn Lin
-
Publication number: 20210292401Abstract: An isolated anti-SCUBE2 antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically binds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting VEGF-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or for use in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.Type: ApplicationFiled: June 8, 2021Publication date: September 23, 2021Inventors: Ruey-Bing YANG, Yuh-Charn Lin
-
Patent number: 11066466Abstract: An isolated anti-SCL)BE2 (Signal peptide-complement protein Clr/CIs, Uegf: and Bmp 1 (CUB)-epidermal growth factor (EGF) domain-containing protein 2) antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically hinds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting vascular endothelial growth factor (VEGF)-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.Type: GrantFiled: April 10, 2017Date of Patent: July 20, 2021Assignee: ACADEMIA SINICAInventors: Ruey-Bing Yang, Yuh-Charn Lin
-
Publication number: 20190127454Abstract: An isolated anti-SCUBE2 (Signal peptide-complement protein Clr/CIs, Uegf: and Bmp 1 (CUB)-epidermal growth factor (EGF) domain-containing protein 2) antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically hinds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting vascular endothelial growth factor (VEGF)-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.Type: ApplicationFiled: April 10, 2017Publication date: May 2, 2019Inventors: Ruey-Bing YANG, Yuh-Charn LIN
-
Publication number: 20140120551Abstract: Methods for determining an increased risk of developing a cardiovascular event excluding stable angina in a subject are disclosed. Also disclosed are methods for diagnosing a human subject's myocardial infarction (MI) and/or acute coronary syndrome (ACS) state or identifying a human subject's risk of MI and/or ACS.Type: ApplicationFiled: October 28, 2013Publication date: May 1, 2014Applicant: ACADEMIA SINICAInventors: RUEY-BING YANG, TE-FA CHIU
-
Publication number: 20130331553Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.Type: ApplicationFiled: January 4, 2013Publication date: December 12, 2013Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Patent number: 8349329Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.Type: GrantFiled: March 3, 2010Date of Patent: January 8, 2013Assignee: Genetech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Patent number: 8211640Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.Type: GrantFiled: December 18, 2008Date of Patent: July 3, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
-
Publication number: 20100234576Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.Type: ApplicationFiled: March 3, 2010Publication date: September 16, 2010Applicant: GENENTECH, INC.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Patent number: 7696327Abstract: The invention relates to the identification and isolation of DNAs encoding the human Toll proteins PR0285, PR0286, and PR0358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PR0285, or PR0286, or PR0358 Toll protein.Type: GrantFiled: October 7, 1998Date of Patent: April 13, 2010Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Publication number: 20090264361Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.Type: ApplicationFiled: December 18, 2008Publication date: October 22, 2009Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
-
Patent number: 7485431Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.Type: GrantFiled: March 22, 2007Date of Patent: February 3, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
-
Publication number: 20070254360Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PR0285, PR0286, and PR0358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PR0285, or PR0286, or PR0358 Toll protein.Type: ApplicationFiled: November 18, 2005Publication date: November 1, 2007Applicant: Genentech, Inc.Inventors: Audrey Goddard, Paul Godowski, Austin Gurney, Melanie Mark, Ruey-Bing Yang
-
Patent number: 7258988Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.Type: GrantFiled: April 3, 2003Date of Patent: August 21, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
-
Publication number: 20070172882Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.Type: ApplicationFiled: March 22, 2007Publication date: July 26, 2007Inventors: Ruey-Bing Yang, Chi Ng, James Tomlinson, Laszlo Komuves, James Topper, Keith Robison
-
Publication number: 20040235104Abstract: The invention provides isolated nucleic acids molecules, designated SEF nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SEF nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SEF gene has been introduced or disrupted. The invention still further provides isolated SEF proteins, fusion proteins, antigenic peptides and anti-SEF antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 7, 2004Publication date: November 25, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventor: Ruey-Bing Yang
-
Publication number: 20030219813Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.Type: ApplicationFiled: April 3, 2003Publication date: November 27, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
-
Publication number: 20030198957Abstract: Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.Type: ApplicationFiled: March 1, 2002Publication date: October 23, 2003Inventors: Ramesh Kekuda, Pamela B. Conley, Ruey-Bing Yang, Matthew Hart, James E. Tomlinson, James Newman Topper, Richard A. Shimkets, Martin D. Leach, Bryan D. Zerhusen, Laszlo Komuves, Muralidhara Padigaru
-
Publication number: 20030165858Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.Type: ApplicationFiled: December 18, 2001Publication date: September 4, 2003Inventors: Muralidhara Padigaru, Valerie L. Gerlach, Glennda Smithson, David Stone, Ruey Bing-Yang, Pamela B. Conley, Matthew Hart, James E. Tomlinson, James Newman Topper, Ramesh Kekuda, Stacie J. Casman, John R. MacDougall, Shlomit R. Edinger
-
Publication number: 20030027260Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.Type: ApplicationFiled: March 11, 2002Publication date: February 6, 2003Applicant: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin Gurney, Melanie Mark, Ruey-Bing Yang